Searcharxiv⌕ Search
Home/Archive/arXiv

arXiv · 2105.12699

Managing Manufacturing and Delivery of Personalised Medicine: Current and Future Models

Andreea Avramescu·Richard Allmendinger·Manuel López-Ibáñez
View original source ↗Read source document ↗Export metadata ↓

Abstract

With almost 50% of annual commercial drug approvals being Personalised Medicine (PM) and its huge potential to improve quality of life, this emerging medical sector has received increased attention from the industry and medical research, driven by health and care services, and us, the patients. Notwithstanding the power of Advanced Therapy Medicinal Products (ATMPs) to treat progressive illnesses and rare genetic conditions, their delivery on large scale is still problematic. The biopharmaceutical companies are currently struggling to meet timely delivery and, given high prices of up to $2 million per patient, prove the cost-effectiveness of their ATMP. The fragility of ATMPs combined with the impossibility for replacements due to the nature of the treatment and the advanced stages of the patient's condition are some of the bottlenecks added to a generally critical supply chain. As a consequence, ATMPs are currently used in most cases only as a last resort. ATMPs are at the intersection of multiple healthcare logistic networks and, due to their novelty, research around their commercialisation is still in its infancy from an operations research perspective. To accelerate technology adoption in this domain, we characterize pertinent practical challenges in a PM supply chain and then capture them in a holistic mathematical model ready for optimisation. The identified challenges and derived model will be contrasted with literature of related supply chains in terms of model formulations and suitable optimisation methods. Finally, needed technological advancements are discussed to pave the way to affordable commercialisation of PM.

Explore related subjects

econ.GNmath.OCq-bio.QMq-fin.EC

Keep this discovery

BibTeXRIS

Andreea Avramescu, Richard Allmendinger, Manuel López-Ibáñez. 2021-05-21. Managing Manufacturing and Delivery of Personalised Medicine: Current and Future Models. https://arxiv.org/abs/2105.12699

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Reducing Prescription Errors Through Information Intervention: A Field Experiment in Healthcare Operations

Drug-drug interaction (DDI) errors pose serious risks to patient safety. Existing decision-support systems often require physicians to respond to alerts, disrupting workflows and contributing to high override rates. We examine whether a non-mandatory information intervention can reduce DDI errors and foster learning. Using a randomized field experiment with India's largest electronic medical record platform, we analyze 2.81 million prescriptions from 1,700 physicians using a difference-in-differences design. Treatment physicians received real-time information highlighting DDI errors without being required to respond, while control physicians received no such information. The intervention reduced DDI errors by 8.6%, corresponding to an estimated US$4.8 million in annual hospitalization cost savings and approximately 134 lives potentially saved. We identify two mechanisms: reactive correction, whereby physicians remove errors after they are flagged, and proactive learning, whereby they avoid errors before alerts occur. While early reductions are driven primarily by correction, physicians increasingly avoid errors over time. They also become less likely to repeat previously flagged errors and reduce new errors, suggesting that learning generalizes beyond specific drug pairs. The effects are consistent across physician types and do not compromise productivity or care quality. Our findings show that non-mandatory information interventions can improve patient safety through both immediate error correction and persistent, generalizable learning.

econ.GN↗
arXiv2026

How an Economy Shrinks in Space: Concavity-on-Jobs and Upward Consolidation under Demographic Decline

When a country's population declines, the aggregate economy appears to contract on the intensive margin: industrial diversity intact, every industry a little smaller. At the regional level, contraction is uneven and takes the extensive form: entire industries disappear, one after another. The relevant unit is the city: industries are nested by size - the hierarchy property of industrial location - each viable only above a minimum population. Necessity industries' thresholds bunch at the low end, so a city's industry count - and its jobs - is sharply concave in size (concavity on jobs). A modest loss pushes a small city below many thresholds at once; a large core sheds a few specialized industries, one at a time. Lost industries consolidate upward to the next city large enough to host them; for the worker it means a step down to a lower-paid local job. To recover that income, workers move up to the apex - the only city hosting the full industry range. Studying Japan - two decades ahead of the OECD, Tokyo at its apex - with worker-level panel data on the young workers who carry the migration, a wage regression in real, housing-inclusive wages identifies a Tokyo-bound migration incentive that varies by origin, following concavity on jobs.

econ.GN↗
arXiv2026

Do wind and solar curtail at negative electricity prices? Incentives and evidence across two decades of German renewable support schemes

In many power systems, wind and solar generation increasingly often exceeds electricity demand. Curtailing renewable generation in those hours matters both for prices and for the physical stability of the grid. Turning off wind turbines and solar panels is technically easier than ramping down a large power station, yet support schemes often give renewables an economic incentive to keep producing at negative prices. This paper studies wind and solar energy in Germany. For each cohort of generators it estimates, hour by hour, the incentive implied by two decades of support policy. It then sets those incentives against observed behavior, using a new estimate of market-based curtailment built from reanalysis weather data. I find that in 2025, at prices below -50 EUR/MWh, almost all wind generators had an incentive to stop producing, but only half of them did. Solar is the opposite case: nearly two thirds of the potential had no incentive to curtail at all, mostly because it receives a feed-in tariff that shields it from wholesale prices. Of the exposed remainder, just over a fifth cut production. Low exposure and response rates inflate subsidy payments and make the power system harder to operate safely. I conclude that a further expansion of wind and solar requires them to respond to price signals.

econ.GN↗